TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Human Milk Fortifiers on Acid-Base Status in Preterm Infants
Brief Summary: Double-blind randomized controlled trial to investigate the impact of two human milk fortifiers on acid-base status and longitudinal growth and weight gain in preterm infants.

Two different compositions are tested, main difference is in electrolyte composiiton.


Options:
A: Intervention Type: DRUG; Name: changing of fortifier; Assigned to Arm(s): N/A
B: Arm Label: Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Parenteral cysteine-HCl supplementation | Arm Label: No-cysteine placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo - added premasol | Intervention Type: DIETARY_SUPPLEMENT; Name: Parenteral cysteine-HCl supplementation; Assigned to Arm(s): Cysteine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo - added premasol; Assigned to Arm(s): No-cysteine placebo
C: Arm Label: Standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard infant formula | Arm Label: Protein-reduced whey formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced whey formula | Arm Label: Protein-reduced α-lactalbumin formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced α-lactalbumin formula | Arm Label: Breast-feeding; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced α-lactalbumin formula; Assigned to Arm(s): Protein-reduced α-lactalbumin formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced whey formula; Assigned to Arm(s): Protein-reduced whey formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard infant formula; Assigned to Arm(s): Standard infant formula
D: Arm Label: Amino Acid Formula; Type: EXPERIMENTAL; Interventions: Other: Amino Acid Formula | Arm Label: Amino Acid commercial formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino Acid formula | Intervention Type: OTHER; Name: Amino Acid Formula; Assigned to Arm(s): Amino Acid Formula | Intervention Type: OTHER; Name: Amino Acid formula; Assigned to Arm(s): Amino Acid commercial formula

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparative Evaluation of Human Thrombin Versus Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Cardiovascular, Neurologic (Spine) and General Surgery Procedures.
Brief Summary: The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in stopping surgical bleeding within 10 minutes of application.


Options:
A: Intervention Type: DRUG; Name: Human Thrombin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bovine Thrombin; Assigned to Arm(s): N/A
B: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
C: Arm Label: IG1202-A (Vascular); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-B (Hepatic); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-C (Soft Tissue); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-D (Spinal); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Intervention Type: BIOLOGICAL; Name: Human thrombin; Assigned to Arm(s): IG1202-A (Vascular), IG1202-B (Hepatic), IG1202-C (Soft Tissue), IG1202-D (Spinal) | Intervention Type: BIOLOGICAL; Name: Bovine thrombin; Assigned to Arm(s): IG1202-A (Vascular), IG1202-B (Hepatic), IG1202-C (Soft Tissue), IG1202-D (Spinal)
D: Intervention Type: DRUG; Name: Fibrin sealant (FS2); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-controlled Trial of Montelukast in Modulating Exacerbations of Asthma in Children, September 2005
Brief Summary: The purpose of the study is to determine if Montelukast added to other therapy, if any, will reduce the severity of asthma symptoms in children during the high incidence of respiratory viral infections that occur in children in the post Labor Day school return period.


Options:
A: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mannitol | Arm Label: Montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): Montelukast
C: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-controlled Trial of Montelukast in Modulating Exacerbations of Asthma in Children, September 2005
Brief Summary: The purpose of the study is to determine if Montelukast added to other therapy, if any, will reduce the severity of asthma symptoms in children during the high incidence of respiratory viral infections that occur in children in the post Labor Day school return period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
C: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
D: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Biological: Omalizumab, Biological: Placebo fluticasone | Arm Label: Inhaled Corticosteroid Boost Therapy (ICS); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Corticosteroid Boost Therapy (ICS), Biological: Placebo omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo omalizumab, Biological: Placebo fluticasone | Intervention Type: BIOLOGICAL; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Inhaled Corticosteroid Boost Therapy (ICS); Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS) | Intervention Type: BIOLOGICAL; Name: Placebo omalizumab; Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS), Placebo | Intervention Type: BIOLOGICAL; Name: Placebo fluticasone; Assigned to Arm(s): Omalizumab, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-controlled Trial of Montelukast in Modulating Exacerbations of Asthma in Children, September 2005
Brief Summary: The purpose of the study is to determine if Montelukast added to other therapy, if any, will reduce the severity of asthma symptoms in children during the high incidence of respiratory viral infections that occur in children in the post Labor Day school return period.


Options:
A: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
B: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Montelukast plus prednisolone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Intervention Type: DRUG; Name: Montelukast plus prednisolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
Brief Summary: Approximately 520 patients will be entered into this study taking place throughout Australia and Europe. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C. difficile-associated diarrhea (CDAD) and lowering the risk of repeat episodes of CDAD. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study related care is provided including doctor visits, physical exams, laboratory tests, and study medication. The total length of participation is approximately 6 weeks.


Options:
A: Intervention Type: DRUG; Name: Tolevamer potassium-sodium (GT267-004); Assigned to Arm(s): N/A
B: Arm Label: fidaxomicin; Type: EXPERIMENTAL; Interventions: Drug: Fidaxomicin, Drug: Matching Placebo to Fidaxomicin | Arm Label: Vancomycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Fidaxomicin; Assigned to Arm(s): fidaxomicin | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Vancomycin | Intervention Type: DRUG; Name: Matching Placebo to Fidaxomicin; Assigned to Arm(s): fidaxomicin
C: Arm Label: GS-CDA1/MDX-1388; Type: EXPERIMENTAL; Interventions: Biological: GS-CDA1/MDX-1388 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: normal saline | Intervention Type: BIOLOGICAL; Name: GS-CDA1/MDX-1388; Assigned to Arm(s): GS-CDA1/MDX-1388 | Intervention Type: BIOLOGICAL; Name: normal saline; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nitazoxanide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Nitazoxanide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prostate Cancer Screening: Fostering Informed Decisions
Brief Summary: The primary goal of this study is to develop and evaluate a print-based method of patient education with a decision tool that is designed to provide detailed information about prostate cancer and to clarify patient preferences and values, ultimately assisting men in making an informed screening decision.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: evidence based decision aid, Behavioral: Possible reimbursement 4th IVF/ICSI cycle when necessary | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: evidence based decision aid; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Possible reimbursement 4th IVF/ICSI cycle when necessary; Assigned to Arm(s): 1
B: Arm Label: RQP-MH; Type: EXPERIMENTAL; Interventions: Behavioral: Right Question Project - Mental Health (RQP-MH) | Arm Label: Comparison Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pamphlet | Intervention Type: BEHAVIORAL; Name: Right Question Project - Mental Health (RQP-MH); Assigned to Arm(s): RQP-MH | Intervention Type: BEHAVIORAL; Name: Pamphlet; Assigned to Arm(s): Comparison Group
C: Arm Label: Computerized decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Informed free choice | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Informed free choice; Assigned to Arm(s): Computerized decision aid
D: Arm Label: Information plus DA at home; Type: EXPERIMENTAL; Interventions: Behavioral: patient decision aid (print-based) | Arm Label: UC Information at home; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: patient decision aid (print-based) | Arm Label: Information plus decision aid at clinic; Type: EXPERIMENTAL; Interventions: Behavioral: patient decision aid (print-based) | Arm Label: UC Information at clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: patient decision aid (print-based) | Intervention Type: BEHAVIORAL; Name: patient decision aid (print-based); Assigned to Arm(s): Information plus DA at home, Information plus decision aid at clinic, UC Information at clinic, UC Information at home

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)
Brief Summary: Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the safety and immunogenicity of GSK Biologicals HPV-16/18 vaccine over 12 months, in pre-teen and adolescent women of 10-14 years of age at study start. Approximately 2000 study subjects will receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule.


Options:
A: Arm Label: Cervarix & Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV Vaccine (GSK580299) Cervarix TM, Biological: Engerix B | Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV Vaccine (GSK580299) Cervarix TM | Arm Label: Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix B | Intervention Type: BIOLOGICAL; Name: HPV Vaccine (GSK580299) Cervarix TM; Assigned to Arm(s): Cervarix & Engerix Group, Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix B; Assigned to Arm(s): Cervarix & Engerix Group, Engerix Group
B: Arm Label: Cervarix Group; Type: OTHER; Interventions: Procedure: Blood sampling | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group
C: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™ | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™; Assigned to Arm(s): Havrix Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age
Brief Summary: This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young as 15 months of age.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Intervention Type: BIOLOGICAL; Name: VARIVAX®; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: M-M-RTM II; Assigned to Arm(s): N/A
B: Arm Label: HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix® | Arm Label: HAV+MMR+V Group; Type: EXPERIMENTAL; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Arm Label: MMR+V→HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): HAV Group, HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: M-M-R®II; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: VARIVAX®; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group
C: Arm Label: V212; Type: EXPERIMENTAL; Interventions: Biological: V212 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: V212; Assigned to Arm(s): V212 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: VAQTA™ (Hepatitis A vaccine), Biological: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Biological: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: VAQTA™ (Hepatitis A vaccine), Biological: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Biological: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine) | Intervention Type: BIOLOGICAL; Name: Comparator: VAQTA™ (Hepatitis A vaccine); Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine); Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine); Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Product (Seretide®) 50/100 mcg With Fluticasone Propionate (Flixotide® ) 200 mcg, Both Delivered Twice Daily Via the DISKUS Inhaler, in the Treatment of Children Aged 6-12 Years With Symptomatic Asthma
Brief Summary: This study is being conducted to investigate whether in childhood salmeterol/ fluticasone propionate 50/100 bd delivered via the Diskus® inhaler and fluticasone propionate 200 mcg bd delivered via the Diskus® inhaler are non- inferior in terms of symptom control. Additionally we aim to show that salmeterol/ fluticasone propionate 50/100 bd is at least as good in terms of lung function improvement and bronchial hyperreactivity and enables a steroid-sparing management of asthma in children.


Options:
A: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo
D: Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
Brief Summary: The main objectives of this study are to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until two years of age and to determine the safety of GSK Biologicals' HRV vaccine with respect to definite intussusception (IS) within 31 days (Day 0-Day 30) after each HRV vaccine dose.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
Brief Summary: The main objectives of this study are to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until two years of age and to determine the safety of GSK Biologicals' HRV vaccine with respect to definite intussusception (IS) within 31 days (Day 0-Day 30) after each HRV vaccine dose.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
D: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: A